Xilio Therapeutics, Inc.
Engineering tumor-activated biologics for cancer to maximize efficacy and minimize toxicity.
XLO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US98422T1007
- LEI:
- Country:
- United States of America
- Address:
- 828 WINTER STREET, 2451 WALTHAM
- Website:
- https://xiliotx.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology (IO) therapies for cancer treatment. The company utilizes its proprietary, clinically validated platform to engineer potent biologics, including masked bispecific antibodies and T cell engagers. These therapies are designed for selective activation within the tumor microenvironment, aiming to concentrate their therapeutic effect on cancer cells while minimizing systemic toxicity. By improving the efficacy-to-toxicity ratio, Xilio seeks to unlock the full potential of powerful immunotherapies for a broader range of patients. The company is advancing a pipeline of novel clinical and preclinical drug candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Xilio Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xilio Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xilio Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
